Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Thrombocythemia Myelofibrosis (PET-MF)”

21 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 21 results

Early research (Phase 1)Study completedNCT01433445
What this trial is testing

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Who this might be right for
Idiopathic MyelofibrosisPost Essential Thrombocythemia MyelofibrosisPost Polycythemia-Vera Myelofibrosis
Novartis Pharmaceuticals 61
Post-approval studies (Phase 4)Study completedNCT01558739
What this trial is testing

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post Polycythaemia Myelofibrosis (PPV MF)Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals 48
Testing effectiveness (Phase 2)Study completedNCT01348490
What this trial is testing

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 66
Testing effectiveness (Phase 2)Looking for participantsNCT06770842
What this trial is testing

Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
The University of Hong Kong 20
Testing effectiveness (Phase 2)Ended earlyNCT02718300
What this trial is testing

INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 74
Testing effectiveness (Phase 2)Study completedNCT03136185
What this trial is testing

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Who this might be right for
MyelofibrosisPost-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)+1 more
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) 90
Large-scale testing (Phase 3)Looking for participantsNCT07357727
What this trial is testing

Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals 460
Early research (Phase 1)Looking for participantsNCT06343805
What this trial is testing

LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Who this might be right for
Primary Myelofibrosis
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company 256
Testing effectiveness (Phase 2)Study completedNCT01445769
What this trial is testing

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Incyte Corporation 45
Testing effectiveness (Phase 2)Study completedNCT01340651
What this trial is testing

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Who this might be right for
Myelofibrosis
Incyte Corporation 41
Testing effectiveness (Phase 2)Ended earlyNCT02226172
What this trial is testing

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Who this might be right for
Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Pfizer 21
Early research (Phase 1)WithdrawnNCT04283526
What this trial is testing

Study of Select Combinations in Adults With Myelofibrosis

Who this might be right for
Primary MyelofibrosisMyelofibrosisPMF+2 more
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Study completedNCT01493414
What this trial is testing

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 2,233
Early research (Phase 1)Ended earlyNCT01730248
What this trial is testing

Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 63
Not applicableLooking for participantsNCT07362225
What this trial is testing

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Who this might be right for
Polycythemia VeraET (Essential Thrombocythemia)Polycythemia Vera (PV)+52 more
MPN Research Foundation 5,000
Testing effectiveness (Phase 2)Study completedNCT03222609
What this trial is testing

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Who this might be right for
Myelofibrosis (MF)
AbbVie 191
Testing effectiveness (Phase 2)Study completedNCT02966353
What this trial is testing

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera-MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals 51
Early research (Phase 1)Study completedNCT01317875
What this trial is testing

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Who this might be right for
Myelofibrosis
Incyte Corporation 69
Testing effectiveness (Phase 2)Study completedNCT01633372
What this trial is testing

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 87
Early research (Phase 1)Study completedNCT02493530
What this trial is testing

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Who this might be right for
MyelofibrosisPolycythemia Vera
Vanderbilt-Ingram Cancer Center 60
Next Page